Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 29
Filtrar
1.
Clin Oral Investig ; 26(10): 6165-6175, 2022 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-35690690

RESUMEN

OBJECTIVES: The aim of the study was to evaluate the dental and bone age delay and occlusal traits of children with growth hormone deficiency (GHD) and idiopathic short stature (ISS). MATERIAL AND METHODS: The study group included 46 patients aged 5 to 14 years: 15 with ISS, 17 with GHD before growth hormone treatment, and 14 with GHD during substitution therapy. The control group consisted of 46 age and sex-matched subjects of normal height. A calibrated dentist assessed all subjects in terms of dental age and occlusal characteristics. Bone age was evaluated only in GHD and ISS children as a part of a hospital's diagnostic protocol. RESULTS: The subgroup of GHD before treatment differed significantly concerning dental age delay from their healthy peers (- 0.34 and 0.83 year, respectively, p = 0.039). Dental age delay in short stature children was less marked than bone age delay (- 0.12 and - 1.76, respectively, p < 0.00001). Dental crowding was recorded in 57% of ISS patients and 53% of GHD children before treatment compared to only 22% of the control subjects (p = 0.027 and p = 0.021, respectively). CONCLUSIONS: Dental age was retarded in GHD children before growth hormone (GH) therapy, but the delay does not seem clinically significant. ISS children and GHD children before therapy showed marked bone age delay and tendency to crowding. CLINICAL RELEVANCE: The different pace of teeth eruption and skeletal growth in short stature children should be considered when planning their dental treatment.


Asunto(s)
Enanismo Hipofisario , Hormona de Crecimiento Humana , Estatura , Niño , Enanismo Hipofisario/diagnóstico , Enanismo Hipofisario/tratamiento farmacológico , Trastornos del Crecimiento/tratamiento farmacológico , Hormona del Crecimiento/uso terapéutico , Hormona de Crecimiento Humana/uso terapéutico , Humanos
2.
Reumatologia ; 59(3): 146-152, 2021.
Artículo en Inglés | MEDLINE | ID: mdl-34538941

RESUMEN

OBJECTIVES: In rheumatic diseases, vitamin D supply is recommended as part of the prophylaxis and treatment of osteoporosis, especially in patients undergoing glucocorticoid therapy, but also due to its immunoregulatory and anti-inflammatory properties. We aimed to evaluate serum 25-hydroxyvitamin D [25(OH)D3] levels in Polish patients with systemic sclerosis (SSc), systemic lupus erythematosus (SLE) and granulomatosis with polyangiitis (GPA), in relation to various clinical parameters, and to assess the initial range of doses for the purpose of further research. MATERIAL AND METHODS: 112 patients (39 with SLE, 44 with SSc and 29 with GPA), referred to the Department of Rheumatology and Internal Medicine in Poznan, Poland, were enrolled in this retrospective study. Demographic and clinical data were collected, including 25(OH)D3 serum levels, vitamin D supplementation doses and season of blood sampling. RESULTS: Mean (SD) serum 25(OH)D3 concentrations were 31 (19.4) ng/ml for SLE, 28.8 (12.5) ng/ml for SSc and 28 (15.2) ng/ml for GPA, and they did not significantly differ between the groups. Vitamin D levels below the optimal range were found in 43.8% of SLE, 65.9% of SSc and 72.4% of GPA patients. 80% of patients reported vitamin D intake, with a mean daily dose of 1398 IU for SLE, 1345 IU for SSc and 1689 IU for GPA. Vitamin D insufficiency and deficiency were frequent among patients with rheumatic diseases, independently of the diagnosis and season. CONCLUSIONS: Patients with rheumatic diseases seem to require higher doses of vitamin D than recommended for the general population. The present results indicate the necessity to use higher initial doses of vitamin D in this group of patients (2000 to 4000 UI) and to maintain the dose of vitamin D regardless of the change of seasons.

3.
BMC Endocr Disord ; 19(1): 137, 2019 Dec 11.
Artículo en Inglés | MEDLINE | ID: mdl-31829163

RESUMEN

BACKGROUND: Body posture may be disordered by vestibular dysfunction, neurological disorders, problems with the distribution of muscle tone, brain injuries, and other dysfunctions. Growth hormone deficiency (GHD) can lead to many disorders, particularly of the musculoskeletal system. During treatment with recombinant human growth hormone (rhGH), an increase in muscle mass and an improvement in bone structure can be observed in children suffering from hypopituitarism from GHD. METHODS: The study involved 33 children suffering from hypopituitarism with GHD (9 girls and 24 boys), aged 10-14 years old. Measurements of the magnitude of their anterior-posterior spinal curvatures were made using an inclinometer. The children were examined at the medianus of the sacrum bone, the Th12-L1 intervertebral area, and the C7-Th1 intervertebral area. In order to characterize the anterior-posterior curvature of the spine, the results were compared with the general norms reported by Saunders. Statistical calculations were carried out using the statistical package Statistica 10 PL. RESULTS: Lumbar lordosis angles were higher in the patients currently receiving growth hormone (GH) treatment than in those who had yet to receive it. There is a statistically significant positive correlation between the length of growth hormone treatment and the alpha angle. There are also statistically significant correlations between age at the beginning of growth hormone therapy and the angle of lordosis. Statistically significant correlations were also seen between age at the beginning of growth hormone therapy and the alpha angle. CONCLUSIONS: Although there may be changes in posture at the beginning of rhGH treatment, the sooner growth hormone therapy begins, the better the body posture. The longer the growth hormone treatment, the better the posture, as expressed by the alpha angle in the sagittal plane.


Asunto(s)
Hormona de Crecimiento Humana/deficiencia , Hormona de Crecimiento Humana/uso terapéutico , Hipopituitarismo/complicaciones , Curvaturas de la Columna Vertebral/fisiopatología , Adolescente , Factores de Edad , Niño , Femenino , Humanos , Hipopituitarismo/fisiopatología , Lordosis/etiología , Lordosis/fisiopatología , Vértebras Lumbares/fisiopatología , Masculino , Postura , Curvaturas de la Columna Vertebral/etiología , Factores de Tiempo
4.
Adv Exp Med Biol ; 1153: 63-67, 2019.
Artículo en Inglés | MEDLINE | ID: mdl-30758773

RESUMEN

Systemic sclerosis is a connective tissue disease characterized by tissue fibrosis leading to interstitial lung disease. Transforming growth factor-ß (TGF-ß) has been of interest as a potential diagnostic marker and also as a drug target in systemic sclerosis. The aim of this study was to assess the serum content of TGF-ß1 in patients with systemic sclerosis and to assess its potential role in tissue fibrosis. The study included 30 patients, 5 men and 25 women, of the mean age of 46.9 ± 12.8 years, diagnosed with systemic sclerosis. The control group consisted of 19 women of the mean age of 28.4 ± 7.8 years, diagnosed with primary Raynaud's disease. TGF-ß1 serum levels were measured, chest imaging examinations were performed, and fibrotic tissue changes were assessed using the modified Rodnan Skin Score. We found that the mean serum TGF-ß1 content in patients with systemic sclerosis was 598.7 ± 242.6 pg/mL, whereas it was 568.4 ± 322.2 pg/mL in the control group (p = 0.378). We also failed to substantiate any significant relationship between TGF-ß1 serum levels and the severity of pulmonary and skin fibrosis in systemic sclerosis. In conclusion, systemic sclerosis does not seem a disease that would be accompanied by a specific enhancement of serum TGF-ß1. Thus, this cytokine is rather unlikely to play an essential role in the development and course of the disease, nor can it be considered diagnostic or prognostic marker.


Asunto(s)
Esclerodermia Sistémica , Factores de Crecimiento Transformadores , Adulto , Femenino , Fibrosis , Humanos , Masculino , Persona de Mediana Edad , Esclerodermia Sistémica/sangre , Piel/patología , Factor de Crecimiento Transformador beta , Factor de Crecimiento Transformador beta1/sangre , Factores de Crecimiento Transformadores/sangre , Adulto Joven
5.
Ther Adv Chronic Dis ; 15: 20406223241229855, 2024.
Artículo en Inglés | MEDLINE | ID: mdl-38560719

RESUMEN

The neuropsychological functioning of people with type 1 diabetes (T1D) is of key importance to the effectiveness of the therapy, which, in its complexity, requires a great deal of knowledge, attention, and commitment. Intellectual limitations make it difficult to achieve the optimal metabolic balance, and a lack of this alignment can contribute to the further deterioration of cognitive functions. The aim of this study was to provide a narrative review of the current state of knowledge regarding the influence of diabetes on brain structure and functions during childhood and also to present possible actions to optimize intellectual development in children with T1D. Scopus, PubMed, and Web of Science databases were searched for relevant literature using selected keywords. The results were summarized using a narrative synthesis. Disturbances in glucose metabolism during childhood may have a lasting negative effect on the development of the brain and related cognitive functions. To optimize intellectual development in children with diabetes, it is essential to prevent disorders of the central nervous system by maintaining peri-normal glycemic levels. Based on the performed literature review, it seems necessary to take additional actions, including repeated neuropsychological evaluation with early detection of any cognitive dysfunctions, followed by the development of individual management strategies and the training of appropriate skills, together with complex, multidirectional environmental support.


Intellectual development in children with type 1 diabetes Disturbances in glucose metabolism during childhood may have a lasting negative effect on the development of the brain and related cognitive functions. To optimize intellectual development in children with type 1 diabetes, it is essential to prevent disorders of the central nervous system by maintaining close to normal glycemic levels. Based on the performed literature review, it seems necessary to take additional actions, including repeated neuropsychological evaluation with early detection of cognitive dysfunctions, followed by the development of individual management strategies, and the training of appropriate skills, together with complex, multidirectional environmental support.

6.
Sci Rep ; 13(1): 14707, 2023 09 07.
Artículo en Inglés | MEDLINE | ID: mdl-37679467

RESUMEN

Growth hormone is meaningfully involved in the processes of tooth cells differentiation and tissue formation. The aim of the study was to evaluate the occurrence of dental anomalies: microdontia, macrodontia, hypodontia and developmental defects of enamel (DDE) amongst a group of isolated growth hormone deficient (GHD) patients and healthy children. This cross-sectional study was based on a group of 101 Caucasian children: 33 with GHD (mean age 10.94, SD 2.51) and 68 being healthy, normal height subjects (mean age 10.4, SD 2.38). The dental examination in primary and permanent teeth was carried out by one trained and calibrated dentist, in accordance with the WHO guidelines. It was observed that 33% of GHD patients suffer from dental anomalies (hypodontia, microdontia or macrodontia), the difference between the study group and the control group was statistically significant (33% vs 4%, p < 0.001). Hypodontia and microdontia/macrodontia were the most common problems affecting 18% and 21% of the GHD individuals, respectively. The prevalence of DDE did not differ significantly between GHD group and the control group (58% vs 48%, p > 0.05). As children with GHD present more dental anomalies than their healthy coevals, clinicians should be aware of the possible oral health problems associated with GHD and consider dental screening and management as part of the patient's overall health care plan.


Asunto(s)
Anodoncia , Escarabajos , Hormona de Crecimiento Humana , Enfermedades Dentales , Humanos , Niño , Animales , Estudios Transversales , Hormona del Crecimiento , Esmalte Dental
7.
Biomedicines ; 11(11)2023 Nov 17.
Artículo en Inglés | MEDLINE | ID: mdl-38002089

RESUMEN

Intellectual functioning studies carried out amongst children indicate that chronic diseases like type 1 diabetes and growth hormone deficiency (GHD), may, but do not necessarily, result in intellectual loss. Cognitive functions may decline as a child becomes older, as a disease persists over time and/or due to non-compliance with treatment recommendations or high stress levels. This study aimed to assess the cognitive functioning of children and youths with T1D and GHD-related short stature compared to healthy children. METHODS: The study was carried out on 88 children with type 1 diabetes, 38 children suffering from short stature caused by (GHD), as well as a control group comprising 40 healthy children. Weschler's tests were applied to measure intellectual and cognitive functions. RESULTS: The results suggest that for children suffering from type 1 diabetes and short stature, their chronic childhood diseases per se do not impair cognitive development. It was observed that the higher the age of chronically ill children and the longer the disease persists, the lower their scores in individual cognitive subtests. For healthy children, age is correlated with the acquisition of particular skills and higher scores in specific subtests. CONCLUSIONS: On the basis of qualitative analysis of the cognitive functions subject to the study and close clinical observation of chronically ill children, we have been able to conclude that chronic diseases may alter cognitive functioning.

8.
Materials (Basel) ; 15(7)2022 Apr 04.
Artículo en Inglés | MEDLINE | ID: mdl-35407984

RESUMEN

Additive manufacturing (AM) polymers are applied in many branches of the industry due to the possibility of fast and accurate production of elements with various and complex shapes. Fibre Bragg grating sensors (FBG) are widely applied in structural health monitoring (SHM) systems. The main objective of this research is to perform analyses of the influence of embedded FBG sensors on AM polymer elements' durability. Two polymers (M3 X and M3 Crystal) with different mechanical properties were analysed. The tests were performed on samples with FBG sensors embedded in (different alignment) and attached to the surfaces of the elements. Firstly, the samples were exposed to elevated or sub-zero temperatures under stable relative humidity levels. The strain in the samples was measured using fibre Bragg grating (FBG) sensors. The achieved results allow us to determine the relationships between strain and temperature for both materials and the differences in their mechanical response to the thermal loading. Then, the samples were subjected to a tensile test. A comparison of the tensile strength values was performed for the samples without and with embedded FBG sensors. The samples after the tensile tests were compared, showing differences in the mechanisms of failures related to the polymers and the thermal treatment influence on the material internal structure. Additionally, strain values measured by the FBG sensors were compared to the strain values achieved from the testing machine showing a good agreement (especially for M3 X) and indicating the differences in the materials' mechanical properties. The achieved results allow us to conclude there is a lack of influence of embedded FBG sensors on the mechanical durability of AM polymers.

9.
Mol Biol Rep ; 38(3): 1793-8, 2011 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-20842437

RESUMEN

Genes encoding adipokines are important functional candidates for development of obesity. In this study we screened for polymorphism 5'-flanking regions of the adiponectin (ADIPOQ), leptin (LEP) and resistin (RETN) genes in a cohort of Polish obese children and adolescents (n = 243) and a control group of non-obese adults (n = 100). Altogether 13 SNPs (single nucleotide polymorphisms) and 1 InDel (insertion/deletion polymorphism) were found. Among them five polymorphisms, localized in the LEP gene, turned out to be novel, but their distribution was insufficient for association studies. We found no consistent evidence for association between obesity and the SNPs demonstrating minor allele frequency (MAF) above 0.2 (ADIPOQ: -11377C>G, LEP: -2548C>T, 19A>G, RETN: -1300G>A, -1258C>T, -420C>G). Comparison of polymorphisms distribution in patients and control group suggested association with ADIPOQ -11377C>G (Pearson test P = 2.76 × 10(-11)), however, we did not observe any effect of this polymorphism on BMI or relative BMI (RBMI) within obese patients (P = 0.41). We conclude that the tested SNPs are not useful markers of childhood and adolescence obesity in Polish population.


Asunto(s)
Región de Flanqueo 5'/genética , Adiponectina/genética , Predisposición Genética a la Enfermedad , Leptina/genética , Obesidad/genética , Polimorfismo de Nucleótido Simple/genética , Resistina/genética , Adolescente , Adulto , Sitios de Unión , Estudios de Casos y Controles , Niño , Femenino , Estudios de Asociación Genética , Humanos , Masculino , Persona de Mediana Edad , Polonia , Regiones Promotoras Genéticas/genética , Factores de Transcripción/metabolismo
10.
PLoS One ; 16(1): e0236617, 2021.
Artículo en Inglés | MEDLINE | ID: mdl-33481810

RESUMEN

Grain of the highest hardness was produced from durum wheat grown without the use of growth regulator, at the lowest sowing density (350 seeds m-2) and nitrogen fertilization dose of 80 kg ha-1. The highest values L* and b* were determined in the grain of wheat cultivated without additional agrotechnical measures (growth regulator and nitrogen fertilization). Study results, supported by correlation analysis, indicated that high-quality grain with desired flour quality parameters (level of: FER ≈ 64%; FPS ≈ 98%; L* ≈ 92) can be produced from spring durum wheat grown without the growth regulator and at 80 kg·ha-1 nitrogen fertilization. Additionally, this variant of applied cultivation system can reduce costs of durum wheat production and contamination of the natural environment.


Asunto(s)
Agricultura/métodos , Triticum/crecimiento & desarrollo , Grano Comestible/química , Ambiente , Europa Oriental , Harina/análisis , Glútenes/análisis , Nitrógeno/análisis , Proteínas de Plantas/análisis , Semillas/crecimiento & desarrollo , Triticum/metabolismo
11.
J Clin Med ; 10(16)2021 Aug 22.
Artículo en Inglés | MEDLINE | ID: mdl-34442031

RESUMEN

Growth hormone (GH) is involved in the regulation of the postnatal dental and skeletal growth, but its effects on oral health have not been clearly defined. This paper aims to provide a review of current clinical knowledge of dental caries, tooth wear, developmental enamel defects, craniofacial growth and morphology, dental maturation, and tooth eruption in growth hormone deficient (GHD) children. A systematic review was carried out using Scopus, MEDLINE-EbscoHost and Web of Science from 2000 to May 2021. PRISMA guidelines for reporting systematic reviews were followed. All the selected studies involved groups under eighteen years of age, covering a total of 465 GHD patients. The studies that were selected provide reliable evidence for delayed dental maturity and orthodontic disturbances in GHD patients. Data on dental hard tissues pathology are scarce and are limited to occurrences of dental caries. GHD children showed abnormal craniofacial morphology with reduced mandibular dimensions, with a resulting tendency towards Angle's Class II occlusion, which affected up to 31% of patients. Dental age has been shown to be delayed in GHD patients by about 1 to 2 years. Moreover, the risk of dental caries in children with GHD decreases with increasing levels of vitamin D. Hence, further studies would be valuable for evaluating the risk of various oral health problems and to organize targeted dental care for this vulnerable group.

12.
Ann Agric Environ Med ; 28(1): 122-126, 2021 Mar 18.
Artículo en Inglés | MEDLINE | ID: mdl-33775077

RESUMEN

INTRODUCTION AND OBJECTIVE: The COVID-19 pandemic causes vital concerns due to the lack of proved, effective, and safe therapy. Chloroquine and hydroxychloroquine seem to be useful, but recently serious concerns regarding their adverse events have risen. The aim of the study was to broaden the general perspective of chloroquine and hydroxychloroquine use in COVID-19 treatment, based on an analysis of their current safety profile among patients with rheumatic diseases. MATERIAL AND METHODS: The study was based on a group of 152 patients with rheumatic diseases, aged 20-78 years, treated either with chloroquine or hydroxychloroquine. Analyzed data included age, gender, comorbidities, type of drug, dosage, treatment duration, and reported adverse events. Cases of drug withdrawal related to adverse events were also recorded. RESULTS: The dosage was consistent in both groups: 250 mg of chloroquine or 200 mg of hydroxychloroquine daily. 77.6% of patients did not experience any adverse reactions to the treatment. Hydroxychloroquine showed better safety profile, with 10.9% of patients reporting side-ffects, compared to 28.9% in patients treated with chloroquine. The overall incidence of ophthalmic complications was 6.6%. For both drugs, no statistically significant correlation between adverse events and age, chronic heart or liver disease, or hypertension was found. CONCLUSIONS: Chloroquine and hydroxychloroquine at lower doses, as used in rheumatic diseases, prove to be relatively safe. Data from the literature show that high dosage as recommended in COVID-19 treatment may pose a risk of toxicity and require precise management, but prophylactic, long-term use of lower, safe doses might be a promising solution.


Asunto(s)
Antirreumáticos/efectos adversos , Cloroquina/efectos adversos , Hidroxicloroquina/efectos adversos , Enfermedades Reumáticas/tratamiento farmacológico , Adulto , Anciano , Antirreumáticos/administración & dosificación , Antirreumáticos/uso terapéutico , Cloroquina/administración & dosificación , Cloroquina/uso terapéutico , Ojo/efectos de los fármacos , Femenino , Humanos , Hidroxicloroquina/administración & dosificación , Hidroxicloroquina/uso terapéutico , Masculino , Persona de Mediana Edad , Tratamiento Farmacológico de COVID-19
13.
Pediatr Endocrinol Diabetes Metab ; 26(3): 113-117, 2020.
Artículo en Inglés | MEDLINE | ID: mdl-32901467

RESUMEN

INTRODUCTION: A significant increase in growth velocity is observed during recombinant human growth hormone (rhGH) therapy in patients with growth hormone deficiency (GHD), especially just after the beginning of treatment. This phenomenon is referred to as catch-up growth". After some time, the growth velocity decreases to the physiological value, i.e. the value that is observed in healthy children. The treatment is continued until the time of the growth process is completed. The continuity of the therapy makes it impossible to assess whether the catch-up phenomenon occurs only at the beginning of the treatment or may be observed after treatment cessation and its re-introduction. MATERIAL AND METHODS: Growth velocity was evaluated in a group of 35 patients with GHD after repeated therapy application, in which, due to non-medical reasons, the rhGH treatment was abandoned for a short time. RESULTS: Patients with GHD after treatment re-introduction presented the catch-up growth phenomenon and obtained growth velocity results that were significantly higher than those observed during primary treatment. CONCLUSIONS: Re-introduction of rhGH treatment after short-term therapy cessation leads to the re-occurrence of catch- up growth in patients with GHD.


Asunto(s)
Enanismo Hipofisario , Hormona de Crecimiento Humana , Estatura , Niño , Enanismo Hipofisario/tratamiento farmacológico , Trastornos del Crecimiento/tratamiento farmacológico , Hormona del Crecimiento , Hormona de Crecimiento Humana/uso terapéutico , Humanos
14.
Medicine (Baltimore) ; 99(37): e22147, 2020 Sep 11.
Artículo en Inglés | MEDLINE | ID: mdl-32925771

RESUMEN

Health disorders in mothers and their children are subject to mutual influences arising from the nature of mother-child relationship. The aim of the study was to analyze the issue of anxiety amongst mothers of short children in aspect of growth hormone (GH) therapy in Poland.The study was based on a group of 101 mothers of originally short-stature children: 70 with GH deficiency treated with recombinant human GH and 31 undergoing the diagnostic process, without any treatment. Collected medical data included the child's gender, height and weight, chronological age, bone age delay, and GH therapy duration. For all children the height SDS (standard deviation score of height) and BMI SDS (standard deviation score of body mass index) were calculated. The Spielberger State-Trait Anxiety Inventory (STAI) was used to evaluate anxiety levels among the recruited mothers. Obtained results revealed low trait anxiety levels in all mothers, with no statistically significant differences between the groups. State anxiety levels were significantly higher in mothers of children without diagnosis and treatment than in mothers of children receiving appropriate therapy. Significantly lower levels of maternal state anxiety were observed during the first stage of the GH therapy, and they were further reduced in mothers of children treated for more than 4 years.Growth failure in Polish children is not associated with high maternal anxiety as a personality trait, but lack of diagnosis and lack of appropriate treatment seem to generate high levels of anxiety as a transient state in mothers. The initiation of GH therapy induces a substantial reduction of maternal state anxiety, and the duration of this treatment causes its further decrease. Mothers of short children undergoing diagnostic process could benefit from psychological support, but it seems to be unnecessary when their children are treated with GH.


Asunto(s)
Ansiedad/epidemiología , Trastornos del Crecimiento/psicología , Hormona del Crecimiento/deficiencia , Hormona de Crecimiento Humana/uso terapéutico , Madres/psicología , Adolescente , Factores de Edad , Estatura , Índice de Masa Corporal , Peso Corporal , Niño , Preescolar , Femenino , Trastornos del Crecimiento/diagnóstico , Trastornos del Crecimiento/tratamiento farmacológico , Humanos , Masculino , Polonia/epidemiología , Factores Sexuales
16.
Endocrine ; 69(1): 157-164, 2020 07.
Artículo en Inglés | MEDLINE | ID: mdl-32338337

RESUMEN

PURPOSE: Short stature in children is a significant medical problem which, without proper diagnosis and treatment, can lead to long-term consequences for physical and psychological health in adult life. Since human height is a polygenic and highly heritable trait, numerous variants in the genes involved in growth-including the growth hormone (GH1) gene-have been identified as causes of short stature. METHODS: In this study, we performed for the first time molecular analysis of the GH1 gene in a cohort (n = 186) of Polish children and adolescents with short stature, suffering from growth hormone deficiency (GHD) or idiopathic short stature (ISS), and a control cohort (n = 178). RESULTS: Thirteen SNP variants were identified, including four missense variants, six in 5'UTR, and three in introns. The frequency of minor missense variants was low (<0.02) and similar in the compared cohorts. However, two of these variants, Ala39Val (rs151263636) and Arg42Leu (rs371953554), were found (heterozygote status) in only two GHD patients. These substitutions, according to databases, can potentially be deleterious. CONCLUSIONS: Mutations of GH1 causing short stature are very rare in the Polish population, but two potentially causative variants need further studies in a larger cohort of GHD patients.


Asunto(s)
Enanismo Hipofisario , Hormona de Crecimiento Humana , Adolescente , Estatura/genética , Niño , Enanismo Hipofisario/genética , Trastornos del Crecimiento/genética , Hormona del Crecimiento , Humanos , Polonia
17.
Pediatr Endocrinol Diabetes Metab ; 25(3): 163-167, 2019.
Artículo en Inglés | MEDLINE | ID: mdl-31769275

RESUMEN

Acquired autoimmune hypothyroidism is rare in early childhood, however, it must be considered in a 4 year old child with medical his-tory of delayed growth, increased somnolence, difficulty concentrating, and reduced activity. We report on the case of full clinical picture of severe hypothyroidism in one of the twins. Thyroid function deteriorated in one of the sisters, resulting in mental, motor and growth slowdown, remaining undiagnosed for about 2 years, while the other sister developed normally. In the reported case, severe hypothy-roidism and growth deficiency were accompanied by celiac disease. Initiation of L-thyroxine therapy resulted in an immediate response that increased the growth velocity by more than 2.2 times. This confirms the dominant role of thyroid hormones over celiac disease in the growth process, as the catch up effect started before gluten free diet was introduced.


Asunto(s)
Enfermedad de Hashimoto/diagnóstico , Tiroiditis Autoinmune/diagnóstico , Tiroxina/uso terapéutico , Preescolar , Dieta Sin Gluten , Femenino , Enfermedad de Hashimoto/dietoterapia , Enfermedad de Hashimoto/tratamiento farmacológico , Humanos , Tiroiditis Autoinmune/dietoterapia , Tiroiditis Autoinmune/tratamiento farmacológico , Gemelos
18.
Chem Biol Interact ; 171(3): 312-24, 2008 Feb 15.
Artículo en Inglés | MEDLINE | ID: mdl-18164699

RESUMEN

The present study was aimed at estimate, based on the rat model of human moderate and relatively high chronic exposure to cadmium (Cd), whether zinc (Zn) supplementation may prevent Cd-induced weakening in the bone biomechanical properties. For this purpose, male Wistar rats were administered Cd (5 or 50 mg/l) or/and Zn (30 or 60 mg/l) in drinking water for 6 and 12 months. Bone mineral density (BMD) and biomechanical properties (yield load, ultimate load, post-yield load, displacement at yield and at ultimate, stiffness, work to fracture, yield stress, ultimate stress and Young modulus of elasticity) of the femoral distal end and femoral diaphysis were examined. Biomechanical properties of the distal femur were estimated in a compression test, whereas those of the femoral diaphysis -- in a three-point bending test. Exposure to Cd, in a dose and duration dependent manner, decreased the BMD and weakened the biomechanical properties of the femur at its distal end and diaphysis. Zn supplementation during Cd exposure partly, but importantly, prevented the weakening in the bone biomechanical properties. The favorable Zn influence seemed to result from an independent action of this bioelement and its interaction with Cd. However, Zn supply at the exposure to Cd had no statistically significant influence on the BMD at the distal end and diaphysis of the femur. The results of the present paper suggest that Zn supplementation during exposure to Cd may have a protective influence on the bone tissue biomechanical properties, and in this way it can, at least partly, decrease the risk of bone fractures. The findings seem to indicate that enhanced dietary Zn intake may be beneficial for the skeleton in subjects chronically exposed to Cd.


Asunto(s)
Cadmio/toxicidad , Diáfisis/efectos de los fármacos , Suplementos Dietéticos , Fémur/efectos de los fármacos , Zinc/administración & dosificación , Absorciometría de Fotón , Administración Oral , Animales , Fenómenos Biomecánicos , Densidad Ósea/efectos de los fármacos , Cadmio/antagonistas & inhibidores , Diáfisis/diagnóstico por imagen , Diáfisis/metabolismo , Modelos Animales de Enfermedad , Relación Dosis-Respuesta a Droga , Fémur/diagnóstico por imagen , Fémur/metabolismo , Masculino , Ratas , Ratas Wistar
19.
Pol Merkur Lekarski ; 20(120): 678-81, 2006 Jun.
Artículo en Polaco | MEDLINE | ID: mdl-17007266

RESUMEN

UNLABELLED: The aim of the study was to analyze the number and proportions of different adrenal tumours resected during the last 10 years in our centre. Besides, we seek correlations between the size of tumours and the age and body mass indexes (BMI) of the examined patients. MATERIAL AND METHODS: The tumours where measured on CT and MRI before surgery, and on pathological examination after resection. The examined group consisted of 69 patients, 22 males and 47 females, mean age 50.51 +/- 12.26 yrs. In 45 (65.22%) cases the right adrenal was affected, in 21 (30.43%)--the left, in 3 (4.35%)--both. RESULTS: 12 adrenocortical cancers, 20 phaeochromocytomas, 9 cortisol-secreting adenomas, 4 aldosteronomas, 18 hormonally inactive adenomas, 6 miscellaneous tumours were found. Malignant tumours where significantly larger than benign (12.20 +/- 6.81 vs 6.71 +/- 5.62 cm, p < 0.005). We observed no correlation between the age and preoperative tumor size (p = 0.1756), between the age and pathological tumor size (p = 0.3601), and between BMI and the preoperative and histopathologic size (p = 0.4204, and p = 0.6478, respectively). CONCLUSIONS: The most common tumour was phaeochromocytoma. Most tumours where found in the right adrenal. The malignant tumours where larger than benign ones. No correlations between age and BMI, and tumour size where demonstrated.


Asunto(s)
Neoplasias de las Glándulas Suprarrenales/cirugía , Neoplasias de las Glándulas Suprarrenales/diagnóstico por imagen , Neoplasias de las Glándulas Suprarrenales/patología , Anciano , Femenino , Humanos , Imagen por Resonancia Magnética , Masculino , Persona de Mediana Edad , Estadificación de Neoplasias , Factores de Tiempo , Tomografía Computarizada por Rayos X
20.
Adv Med Sci ; 61(1): 117-22, 2016 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-26647091

RESUMEN

PURPOSE: Leptin and adiponectin are adipokines presenting a wide range of impacts, including glycemic balance regulations. Insulin is one of the main regulators of adipose tissue function. In type 1 diabetes mellitus (T1DM) endogenous insulin secretion is replaced by the exogenous supply, which is not regulated naturally. The aim of the study was to establish serum leptin and adiponectin levels, and their relations to body fat mass and disease course in children with T1DM. MATERIAL/METHODS: The study included 75 children with T1DM and the control group of 20 healthy coevals. All children had estimated serum leptin and adiponectin concentrations, lipid profile, and bioelectrical impedance analysis. RESULTS: Serum leptin concentrations in children with T1DM were not significantly different from the control group (p=0.067, mean values±SD: 3.11±2.98 vs. 5.29±5.06µg/l, respectively), and related positively to body fat mass in both groups. Adiponectin serum concentrations were significantly higher in children with T1DM than in the control group (p<0.001; mean values: 18.82±9.31 vs. 12.10±5.53µg/ml, respectively), and were not related to the body fat content in the study group. Both, leptin and adiponectin, showed no relation to any of the analyzed parameters of the disease course. CONCLUSIONS: Differences observed between children with T1DM and their healthy coevals, when similar in terms of age, body weight, and body fat mass, seem not to depend directly on the disease duration, its metabolic control or insulin supply.


Asunto(s)
Adiponectina/sangre , Adiposidad , Diabetes Mellitus Tipo 1/sangre , Diabetes Mellitus Tipo 1/patología , Progresión de la Enfermedad , Leptina/sangre , Estudios de Casos y Controles , Niño , Colesterol/sangre , Femenino , Humanos , Masculino , Triglicéridos/sangre
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA